OncoArendi and Galapagos enter into exclusive collaboration on chitinase inhibitors in fibrosis
November 05 2020 - 4:15PM
Mechelen, Belgium and Warsaw, Poland, 5
November 2020, 22.15 CET – Galapagos NV (Euronext & NASDAQ:
GLPG) and OncoArendi Therapeutics SA (WSE: OAT), announced that
they have signed an exclusive collaboration and license agreement
for the global development and commercialization of OncoArendi’s
OATD-01. OATD-01 is a Phase 2-ready chitotriosidase/acidic
mammalian chitinase (CHIT1/AMCase) inhibitor for the treatment of
idiopathic pulmonary fibrosis (IPF) and other diseases with a
fibrotic component.
Lung diseases like IPF are associated with an
increased chitinase activity, which strongly correlates with
disease stage, progression and prognosis. Chitinases (predominantly
CHIT1) are involved in macrophage activation. Inhibition of
chitinase activity translates into a potential therapeutic benefit,
as shown in a range of preclinical models. OATD-01 has shown robust
anti-fibrotic activity in multiple animal models, when compared
with the standard of care.
OncoArendi has developed a portfolio of
CHIT1/AMCase inhibitors, of which OATD-01 is the first-in-class
frontrunner. OATD-01 is a novel, small molecule CHIT1/AMCase
inhibitor targeting a key pathway in tissue remodeling. It has
shown compelling translational data, a favorable profile in animal
studies at expected therapeutic doses and it has successfully
completed Phase 1 studies in healthy volunteers. Galapagos aims to
bring OATD-01 to a Phase 2 clinical trial for the treatment of IPF
and possibly other diseases with a fibrotic component.
Walid Abi-Saab, Chief Medical Officer of
Galapagos said: “Galapagos is very excited to gain access to
OATD-01 and OncoArendi’s innovative pipeline of novel chitinase
inhibitors, further strengthening and complementing our existing
fibrosis portfolio. Bringing OATD-01 to our pipeline supports our
ambition to lead the advancement of treatments in fibrosis
and continues to show our commitment to push boundaries in the
fight against IPF, a debilitating and fatal disease”.
“Converging human biology and preclinical data
indicate that chitinases are highly relevant therapeutic targets
for a range of inflammatory and fibrotic diseases. This unique area
of disease biology enables development of novel therapies in
biomarker-driven patient populations. OncoArendi is excited about
the ability to tap into the scientific and clinical development
expertise of Galapagos and we enthusiastically look forward to this
long-term strategic collaboration in maximizing the potential of
chitinase and chitinase-like proteins in treatment of severe human
diseases involving organ fibrosis” said Marcin Szumowski, CEO of
OncoArendi.
In exchange for global research, development and
commercialization rights, OncoArendi will receive an upfront
payment of €25 million and will be eligible to receive development,
regulatory and commercial milestones on licensed products, for a
total potential deal value of €320 million. OncoArendi is also
eligible to receive tiered royalties ranging up to low
double-digits, based on future net sales.
Additionally, under the terms of the agreement,
Galapagos will pay OncoArendi €2 million for the right of first
negotiation on all other earlier stage programs on its chitinase
platform. OncoArendi remains responsible for all research activity
until preclinical candidate selection, after which Galapagos
can exercise the option to initiate negotiations to obtain
development or commercialization rights for the selected molecules.
Any such transaction will be subject to a separate set of
payments.
About GalapagosGalapagos
(Euronext & NASDAQ: GLPG) discovers and develops small molecule
medicines with novel modes of action, several of which show
promising patient results and are currently in late-stage
development in multiple diseases. The company’s pipeline comprises
early discovery through to Phase 3 programs in inflammation,
fibrosis, and other indications. Galapagos’ ambition is to become a
leading global biopharmaceutical company focused on the discovery,
development and commercialization of innovative medicines. More
information at www.glpg.com.
About OncoArendi
OncoArendi Therapeutics SA (WSE:OAT) is a Polish
innovative biotechnology company specializing in research,
development and commercialization of innovative small molecule
drugs for treatment of respiratory diseases and
cancer. Researchers at OncoArendi study the role of
chitinases and chitinase-like-proteins that provide multiple
opportunities for therapeutic interventions. OncoArendi currently
has a platform of distinct small molecule programs targeting this
classes of proteins, which may have potential utility in diverse
inflammatory and fibrotic diseases of high unmet medical need.
OncoArendi is also focusing on the development of small molecule
immune-modulators targeting a key enzyme involved in amino acid
metabolism that allows tumor cells to hamper anti-tumor immunity
and to avoid immune surveillance. OncoArendi Therapeutics' business
model is based on the discovery and development of first-in
class or best-in-class small molecules, and then
outlicensing its assets to larger pharmaceutical and biotechnology
companies. The company has been listed on the WSE main market
since April 2018. More information at www.oncoarendi.com.
Contacts Galapagos |
|
Investors: |
Media: |
Elizabeth Goodwin |
Carmen Vroonen |
VP Investor Relations |
Global Head of Communications & Public Affairs |
+1 781 460 1784 |
+32 473 824 874 |
|
|
Sofie Van Gijsel |
Anna Gibbins |
Senior Director Investor Relations |
Senior Director Therapeutic Areas Communications |
+32 485 19 14 15 |
+44 7717 801900 |
ir@glpg.com |
communications@glpg.com |
|
|
Contacts OncoArendi |
|
Investors: |
Media: |
Nicolas Beuzen |
Marta Borkowska |
Director Business Development |
Director Operations and Communication |
+48 786 811 090 |
+48 728 728 143 |
n.beuzen@oncoarendi.com |
m.borkowska@oncoarendi.com |
Forward-looking statements
This press release includes forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, that are subject to risks,
uncertainties and other factors that could cause actual results to
differ materially from those referred to in the forward-looking
statements and, therefore, the reader should not place undue
reliance on them. These risks, uncertainties and other factors
include, without limitation, the risk that ongoing and future
clinical studies with OATD-01 may not be completed in the currently
envisaged timelines or at all, the inherent uncertainties
associated with competitive developments, clinical trial and
product development activities and regulatory approval requirements
(including that data from the ongoing and planned clinical research
programs may not support registration or further development of
OATD-01 due to safety, efficacy or other reasons), and that
Galapagos’ estimations regarding its ability to bring OATD-01 to a
Phase 2 clinical trial for the treatment of IPF and possibly other
fibrotic diseases, may be incorrect, as well as those risks and
uncertainties identified in our Annual Report on Form 20-F for the
year ended 31 December 2019 and our subsequent filings with the
SEC. All statements other than statements of historical fact are
statements that could be deemed forward-looking statements. The
forward-looking statements contained herein are based on
management’s current expectations and beliefs and speak only as of
the date hereof, and Galapagos makes no commitment to update or
publicly release any revisions to forward-looking statements in
order to reflect new information or subsequent events,
circumstances or changes in expectations.
- OncoArendi and Galapagos enter into exclusive collaboration on
chitinase inhibitors in fibrosis
Galapagos (EU:GLPG)
Historical Stock Chart
From Sep 2024 to Oct 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Oct 2023 to Oct 2024